FIELD: pharmaceutical industry.
SUBSTANCE: group of inventions refers to a pharmaceutical composition for improving the amplitude of accommodation of a lens or for treating or preventing presbyopia in a subject, which contains (in wt % of weight of composition): choline ester of lipoic acid (1–10 %), non-aqueous excipient selected from glycerine (0.1–5 %) or mixture of glycerine and propylene glycol (0.5–5 %), and alanine (0.1–5 %), where said components are mixed with aqueous solution having pH from 4 to 6. Also disclosed are a method of improving the amplitude of lens accommodation and a method of treating or preventing presbyopia in a subject, comprising a step, on which an effective amount of the declared pharmaceutical composition is respectively introduced into the lens of eye or eye of the subject.
EFFECT: group of inventions provides stability of composition during storage (at least 95 % of the initial amount of choline ester of lipoic acid is present in the composition by HPLC after storage at 25 °C and 40 % relative humidity for 3 months).
9 cl, 10 ex, 13 tbl, 5 dwg
Title | Year | Author | Number |
---|---|---|---|
STABLE FORMULATIONS OF BORTEZOMIB | 2011 |
|
RU2529800C2 |
AMINE SALTS OF CRTH2 ANTAGONIST | 2008 |
|
RU2468013C2 |
CLEVIDIPINE NANOPARTICLES AND THEIR PHARMACEUTICAL COMPOSITIONS | 2015 |
|
RU2759673C2 |
COMPOSITIONS AND METHODS FOR TREATING VISUAL ORGAN DISORDERS | 2018 |
|
RU2761436C1 |
OPHTHALMIC COMPOSITION | 2012 |
|
RU2639472C2 |
STORAGE OF STABLE PREPARATION OF PROSTAGLANDIN | 2010 |
|
RU2482851C2 |
TOSYLATE SALT OF TRANS-N-ISOBUTYL-3-FLUORO-3-[3-FLUORO-4-(PYRROLIDIN-1-YLMETHYL)PHENYL]CYCLOBUTANE CARBOXAMIDE | 2008 |
|
RU2451016C2 |
OPHTHALMIC COMPOSITIONS CONTAINING PROSTAMIDE RELEASING NITROGEN OXIDE | 2019 |
|
RU2781022C2 |
ABIRATERONE ACETATE FORMULATION | 2014 |
|
RU2732136C2 |
COMPOSITIONS, APPLICATORS, SETS WITH CONJUGATED ESTROGEN AND METHODS OF THEIR OBTAINING AND APPLICATION | 2006 |
|
RU2420292C2 |
Authors
Dates
2020-11-09—Published
2015-03-03—Filed